Entry Point Capital, LLC Janux Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,649 shares of JANX stock, worth $82,466. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,649Holding current value
$82,466% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
161Shares Held
36.8MCall Options Held
72.2KPut Options Held
103K-
Ra Capital Management, L.P. Boston, MA9.17MShares$458 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$149 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$117 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$116 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$90.1 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.08B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...